Calculate alteplase dose math for acute ischemic stroke and massive PE, including the weight-based stroke total and fixed PE reference dose.
Tissue plasminogen activator (tPA, alteplase) is used in acute ischemic stroke and is also used in massive pulmonary embolism. For stroke, the common reference dose is weight-based (0.9 mg/kg, maximum 90 mg).
This page stays focused on that dosing arithmetic. It helps you cross-check the weight-based stroke total and the common PE reference total without treating the calculator like a stand-alone thrombolysis pathway.
Alteplase dosing is one of the easiest parts of the review to calculate but one of the hardest to do calmly under time pressure. This page keeps the weight-based math and total-dose reference together so the arithmetic can be cross-checked quickly without turning the page into a treatment pathway.
Stroke: Total dose = 0.9 mg/kg (max 90 mg) PE: Common reference total dose = 100 mg
Result: Total: 72 mg
80 kg × 0.9 mg/kg = 72 mg total. Final alteplase use still depends on imaging, exclusion review, and the local reperfusion process.
This page is strongest as a dosing worksheet. It makes the weight-based stroke math explicit and keeps the total-dose reference visible so users do not need to redo the arithmetic under pressure.
Alteplase review still requires imaging, exclusion review, neurologic assessment, and the process used by the treating service. The page therefore works best as a math cross-check once the team has already identified which formal process applies.
Stroke and pulmonary embolism use alteplase differently. The same drug name appears in both settings, but the timing, exclusions, and monitoring expectations are not interchangeable.
Last updated:
This page performs alteplase dose arithmetic only. For acute ischemic stroke it applies the standard 0.9 mg/kg formula with the 90 mg cap; for pulmonary embolism it keeps the common fixed-dose 100 mg reference visible so the arithmetic can be checked quickly.
The page does not determine eligibility, bleeding risk, or whether thrombolysis should be used. Imaging, timing, contraindications, and the formal reperfusion pathway still control that decision.
Stroke commonly uses 0.9 mg/kg (max 90 mg), while PE references often use a fixed 100 mg total. The difference reflects the disease setting, trial history, and pathway assumptions behind each indication rather than a single universal alteplase formula.
Eligibility depends on imaging, timing, exclusion review, and the formal process being used by the treating team. This page stays focused on the arithmetic because the total dose is one of the easiest parts to cross-check without turning the calculator into a treatment workflow.
Tenecteplase (TNK) is increasingly used off-label for stroke because it is given as a single bolus and has a longer half-life. Some institutions now use it in place of alteplase, but actual drug choice still depends on the local workflow.
Those details belong to eligibility review, not dose arithmetic. This page stays focused on the math so it can be used as a reference cross-check without pretending to replace the full alteplase workflow.
Large-vessel-occlusion workflows often include thrombectomy review out to 24 hours in selected patients, but that still depends on imaging and local stroke workflow. This page is only a dosing worksheet and does not decide whether alteplase or thrombectomy should be used.
Bleeding-risk review depends on far more than a few bedside variables. Imaging findings, exclusion criteria, timing, clinical context, and the exact process being used all matter, so this page leaves that assessment outside the calculator.